多发性骨髓瘤中浆细胞增殖和凋亡指数的联合测量可定义预后良好和不良的患者。
Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis.
机构信息
Department of Internal Medicine III, University Hospital Olomouc, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic.
出版信息
Leuk Res. 2011 Jan;35(1):44-8. doi: 10.1016/j.leukres.2010.04.015. Epub 2010 May 21.
We assessed plasma cell proliferation (by propidium iodide index, PC-PI) and apoptosis (by annexin-V index PC-AI) for the estimation of overall survival (OS) in multiple myeloma (MM) patients. 181 patients with newly diagnosed MM were assessed, treated using conventional chemotherapy. The values best discriminating patients with poor prognosis were PC-PI>3.0% and PC-AI<4.75%, and for good prognosis PC-PI≤3.0% and PC-AI≥4.75%. The median OS was 8 months vs 40 months, p=0.0002. Our results suggest that combined measurement of plasma cell proliferation and apoptosis creates a unique strong prognostic factor based on growth characteristics of the tumor clone.
我们评估了浆细胞增殖（通过碘化丙啶指数，PC-PI）和凋亡（通过膜联蛋白-V 指数 PC-AI），以估计多发性骨髓瘤（MM）患者的总生存期（OS）。对 181 例新诊断的 MM 患者进行了评估，采用常规化疗进行治疗。区分预后不良患者的最佳值为 PC-PI＞3.0%和 PC-AI＜4.75%，而对预后良好的患者，PC-PI≤3.0%和 PC-AI≥4.75%。中位 OS 为 8 个月与 40 个月，p=0.0002。我们的结果表明，浆细胞增殖和凋亡的联合测量根据肿瘤克隆的生长特征创建了一个独特的强预后因素。
Zotero 插件